275386-75-9

Usage

Uses

Used in Pharmaceutical Development:
1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one is utilized as a chemical intermediate in the design and development of new drugs, leveraging its unique structural features to explore novel therapeutic agents. The presence of fluorine and iodine atoms may confer specific pharmacokinetic and pharmacodynamic properties, such as enhanced lipophilicity or target binding affinity, which are crucial for drug efficacy and safety.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one serves as a valuable probe for studying the structure-activity relationships of indole-based compounds. Its synthesis and modification can provide insights into the role of heteroatoms in modulating biological activity, thereby guiding the optimization of lead compounds for various therapeutic targets.
Used in Pharmacological Studies:
1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one is employed in pharmacological research to investigate its potential biological activities and mechanisms of action. Given its structural novelty, 1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one may exhibit unforeseen interactions with biological targets, offering opportunities to discover new modes of action or therapeutic indications.

Upstream product

• 131387-94-5 1-hydroxy-4-iodooxindole 
• 144-55-8 sodium hydrogencarbonate 

Relevant academic research and scientific papers

A new series of potent oxindole inhibitors of CDK2

A novel series of oxindole-type inhibitors of CDK2 that have heteroatom substituted alkynyl moieties at their C-4 position is described. These novel 4-alkynyl-substituted inhibitors have superior potency relative to their parent compound in free enzyme and in cell based assays. The crystal structure of CDK2 in complex with one of these analogues was determined and gives insight to their increased potency. The biochemical evaluation of a representative derivative is also described.

PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF

The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF

The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, espe

4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles

Disclosed are 4- and 5-alkynyloxindoles as well as 4- and 5-alkenyloxindoles that inhibit or modulate protein kinases, in particular JNK protein kinases. The compounds of the invention and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing the foregoing compounds, methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis using these compounds, as well as intermediates useful in the preparation of compounds of the invention.

4-Alkenyl- and 4-alkynyloxindoles

Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.